BACKGROUND: Although intentional weight reduction improves obesity-related comorbidities, the associations between weight reduction, medication and related costs are rarely studied. This study investigates the long-term effects of weight change on medication for diabetes and cardiovascular disease (CVD) in severely obese subjects. METHODS: In the intervention study Swedish Obese Subjects, 510 surgically and 455 conventionally treated obese patients have so far been followed for 6 y. Changes in the use and costs of medication were analyzed in relation to treatment and weight change. RESULTS: In comparison with controls, larger fraction of surgically treated patients discontinued the use of medication for CVD and diabetes at 2 and 6 y (risk ratios 0.56 -0.77). Among subjects not initially on medication, surgery reduced the frequency of started treatments (risk ratios 0.08 -0.80). Relative weight loss 10% was necessary to reduce costs of medication for CVD and diabetes among subjects with such treatment at baseline. To reduce initiation of new treatment against the two conditions, weight loss 15% was required. Over 6 y, the average annual cost for diabetes and CVD medication increased by 463 SEK (96%) in subjects with weight loss < 5%, and decreased by 39 SEK(8%) in the weight loss group 15%. CONCLUSION: Long-term intentional weight loss is associated with reduced medication and medication costs for diabetes and CVD. The effects appear to be more marked among subjects who are initially on medication for these conditions, whereas greater weight reduction is needed to prevent new subjects from starting on medication.
Introduction
The prevalence of obesity is increasing in industrialized countries and in most developing countries 1 -5 The increasing number of obese people is likely to increase the burden of obesity-related diseases and conditions such as lipid disturbances, type 2 diabetes, hypertension and other cardiovascular disease, 5 -7 gallbladder disease, 8 osteoarthritis 6 and certain types of cancer. 7, 9 These medical conditions are costly to treat, and it has been estimated that about 1 -6% of the total healthcare expenditures in affluent countries are attributable to obesity. 10 -15 A marked reduction in obesity-related comorbidities after intentional weight loss has been shown. 16 -19 Effects of weight loss on use of medication and pharmaceutical costs are more sparsely studied. A recent study showed that weight loss up to 10% of initial weight resulted in a clear reduction of medication and medication costs for type 2 diabetes and hypertension at 1 y follow-up. 20 Similarly, an average weight loss of 9 kg over 1 y was associated with reduced medication costs for hypertension and diabetes. 21 Little information is available on the long-term effects of weight loss on pharmaceutical costs and other direct and indirect costs of obesity.
In this study, we present the 2 and 6 y effects of weight change on costs and use of medication for diabetes and cardiovascular disease (CVD) among severely obese subjects.
Materials and methods

Swedish Obese Subjects (SOS)
The SOS project is an ongoing nationwide intervention trial, aiming to determine whether the mortality and morbidity rates among persons who reduce their weight by surgical means differ from the rates among persons who receive conventional treatment. The SOS project was started in 1987 and consists of two parts: a cross-sectional registry study and a controlled, prospective intervention study.
The registry study is a survey of 6322 obese subjects including extensive questionnaires and a health examination at primary health care centers. From the registry study, subjects are recruited into the intervention study. In the intervention study, 2010 surgically treated, obese patients will be compared over 20 y with a control group of 2038 matched obese patients who are offered conventional treatment at their primary health care centers. The inclusion criteria for the intervention study were: age 37 -60 y and BMI 38 kg=m 2 for women and BMI 34 kg=m 2 for men. The exclusion criteria for patients in the intervention study were: previous bariatric surgery; previous gastric operation; gastric or duodenal ulcer in the past 6 months; active malignancy in the past 5 y; myocardial infarction in the past 6 months; bulimic eating pattern; abuse of alcohol or narcotics; psychosocial problems suspected to result in poor cooperation; regular use of cortisone or non-steroidal anti-inflammatory medications; and other severe illness. The study involves 480 primary healthcare centers and 25 surgical departments throughout Sweden. The SOS study design, methods for patient selection, and data quality control are described in detail elsewhere.
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Patients who met the inclusion criteria and volunteered for surgery were invited to discuss bariatric surgery with a surgeon, and subjects subsequently accepted for surgery formed the surgical group. The treatment offered to the surgical group included gastric bypass, vertical banded gastroplasty and gastric banding, 23 as preferred by the surgeon. A conventionally treated control group was then selected from the remaining patients in the registry study by a computerized matching procedure, taking into account gender and 18 matching variables related to morbidity and mortality. The subjects were not individually matched, instead the purpose of the matching procedure was to make the two groups as comparable as possible with regard to the mean levels of the matching variables. The variables used in the matching procedure, apart from gender, were age, height, weight, waist and hip circumferences, waist -hip ratio, systolic blood pressure, total serum cholesterol, triglycerides, smoking, diabetes, pre-=post-menopausal state among women, four psychosocial variables and two personality traits related to treatment preferences. 24 Treatment in the control group is not standardized. The subjects receive treatment as obese patients at different primary care centers according to the local practices (which could be dietary advice, behavior modification, very-lowcaloric diet and physical training according to local practices). Pharmacological weight reduction were not available in Sweden during the study period.
Present study group
The study group consists of consecutive subjects who were included in the SOS intervention study during the time period 1987 -1992. Potentially, all 647 surgery cases and 647 controls would have been followed for 6 y. Due to mortality and drop out, the 6 y data were not available for 192 subjects (29.7%) in the control group and for 137 subjects (21.2%) in the surgery group. Only subjects who had completed the 6 y follow-up were included in this report.
Measurements
Body weight, rounded off to the nearest 0.1 kg, was measured with the subjects wearing indoor clothing and no shoes. Height measurements were rounded off to the nearest 0.01 m. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters.
Information on medication and type, dosage, and strength of medicine were collected from questionnaires filled out by the subjects at inclusion, 2 and 6 y follow-up. All drugs were classified according to the Anatomic Therapeutic Classification system (ATC). 25 For diabetes, the subjects gave information on the mode of treatment (insulin, oral glucose-lowering drugs and diet), and a list of the specific drugs used. Drugs in ATC group A10, comprising among others insulin, biguanides and sulfonylureas, were included in the definition of medication for diabetes.
Medication for cardiovascular disease (CVD) included drugs from ATC groups C01 -C03 and C07 -C09, ie cardiac therapy, antihypertensives, diuretics, beta blocking agents, calcium channel blockers, and agents acting on the reninangiotensin system.
The costs per day for every subject were calculated for each specific drug and dosage used. Drug costs were taken from the 1997 official price list of the National Corporation of Swedish Pharmacies. When necessary due to deregistration of drugs an earlier price list was used and the prices converted into 1997 price levels by means of the Swedish consumer price index. Costs per day for diabetes drugs and cardiovascular drugs were then summed up separately for each subject and occasion. The questionnaire on drug usage refers to the 3 month period preceding the examination. Assuming that the use of medication had been the same over the whole year, the daily costs were summed up to estimate the total cost per year. All costs are given in Swedish crowns Among those 965 subjects who completed the 6 y followup, information on costs for CVD medication was not available for 11 and six subjects at 2 and 6 y follow-ups, respectively. Similarly, 14 and 13 subjects had missing data on cost for diabetes medication at 2 and 6 y follow-ups, respectively. Further, among those who completed the 6 y follow-up, five subjects had missing data on weight, and 4
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Statistical analyses
Differences in the proportion of subjects on medication at follow-up were compared in a generalized linear model for binary outcomes. 26 In the model, the probability of being on medication is related to the covariates through a link function. We used a logarithmic link function (binomial regression), and thus we report risk ratios (alternatively, use of logit link function would result in a logistic regression model and odds ratios). In addition to the treatment group, age, sex and body mass index at the baseline were included as covariates in the model. In cases involving small numbers of events, exact conditional methods were used to calculate confidence intervals for relative risks. 27 After pooling data from the control and surgical groups, changes in the use of medication were analyzed in relation to weight change. Weight change variables were categorized into four groups: weight loss < 5% (including subjects who gained weight), 5 -10%, 10 -15% and 15%. Measurement of weight used to calculate relative weight loss is 2 y weight for analyses regarding the 2 y follow-up, and similarly 6 y weight for analyses of the 6 y follow-up. In all comparisons of the four weight loss groups, the < 5% group was used as a reference group.
When comparing medication costs and changes in cost in different weight loss groups, we report mean values in each group. Due to skewed distribution of the cost variables, with many zero values, statistical tests of equality between the weight loss groups were done by constructing confidence intervals based on bootstrap percentiles. 28 The number of bootstrap samples was set at 1000.
All calculations on changes in use of medication and cost for medication were done separately for those on and not on medication at the baseline. Analyses were performed using the statistics packages Stata 29 and StatXact. 27 
Human subjects
The study was performed according to the Declaration of Helsinki and was approved by the ethical committees of all participating universities in Sweden. Subjects gave their informed consent.
Results
The clinical characteristics of the 455 controls and 510 surgically treated subjects who completed the 6 y follow-up are shown in Table 1 . At the baseline, the proportion of men was similar in both groups, whereas the control group had slightly higher mean age. The surgical group had higher mean levels of body mass index, systolic and diastolic blood pressure and fasting blood glucose. The proportions on medication for CVD and diabetes were similar in both groups. On average, there were no changes in body weight in the control group, whereas the surgery group had a mean relative weight loss of 22 and 16% at 2 y and 6 y follow-ups, respectively. In the control group, 19% of the subjects achieved a weight reduction of more than 5% at 2 y followup, and 8% had a weight loss more than 10% of the initial weight. The corresponding percentages at 6 y follow-up were 25 and 11%.
Subjects not available to evaluation at 6 y follow-up had similar characteristics at the inclusion to the study regarding age, sex and BMI as compared to subjects who completed the follow-up. Further, the proportion on CVD and diabetes medication at the inclusion did not differ significantly among those who completed the follow-up as compared to the drop-outs. Effects of weight loss on pharmaceutical costs in obese subjects G Å gren et al
Changes in use of medication were more favorable in the surgery group as compared to the control group (Table 2) . Among subjects with CVD medication at the baseline, the proportion on medication at the 2 y follow-up was 91.2% in the control group as compared to 61.7% in the surgery group. The corresponding proportions at 6 y follow-up were 86.4 and 64.7% in the control and surgery group, respectively. Among subjects without CVD medication at the baseline, the proportions of subjects who were on medication at the 2 y follow-up were 10.1 and 3.1% in the control and surgery groups respectively. However, this difference between the groups was reduced and did not reach statistical significance at 6 y follow-up.
In the control group, all subjects who were on medication for diabetes at the baseline continued to use medication at 2 and 6 y follow-ups ( Table 2 ). The corresponding proportions in the surgery group were 56.2 and 68.8%. Among subjects initially free from medication for diabetes, the use of medication at 6 y follow-up was five times more common in the control group as compared to the surgery group.
In sex-specific analyses, the proportion of surgically treated men who continued the use of medication for diabetes after 2 y was 29%, as compared to 64% among surgically treated women. However, the number of subjects was low, and this sex difference did not reach statistical significance (P-value 0.191 for sex-treatment interaction term). The effects of surgical treatment on CVD medication were similar in both sexes.
After combining the control and surgical groups, weight change over 2 and 6 y was used to categorize all subjects into four weight loss groups. For subjects on CVD medication at the baseline, there was a decrease in the continued use of medication both at 2 and 6 y follow-up in groups with weight loss 10% as compared to the reference group with weight loss < 5% (Figure 1) . Similarly, at 2 y follow-up all subjects on medication for diabetes at the baseline continued to use medication in the weight loss groups < 5% and 5 -10%, whereas in the groups with weight loss 10%, only 53% remained on medication at follow-up (Figure 1) . However, these differences were reduced at 6 y follow-up, and did not reach statistical significance.
Among subjects not on CVD medication initially, a weight loss 15% was required to achieve an improvement in comparison to the reference group (Figure 2) . The proportions on CVD medication were 8.3 and 16.6% at 2 and 6 y follow-up, respectively, in the < 5% group, compared to 3.9% and 10.0% in the 15% group (adjusted risk ratio -2 y, 0.43, 95% CI 0.21 -0.87; 6 y, 0.59, 95% CI 0.36 -0.98). Among those initially free from medication for diabetes, around 4% started medication after 2 y in the groups with weight loss < 10%, whereas only 0.2% in the weight loss groups 10% started medication (adjusted risk ratio 0.08, 95% CI 0.01 -0.64, Figure 2) .
The average cost for CVD medication at the baseline ranged from 1452 to 1961 SEK per year in the four weight loss groups (not statistically significant; Table 3 ). After 2 y, the cost per year was 1735 SEK in the < 5% group as compared to 930 in the 15% group. The difference in the change between these two groups, adjusted for sex, age, BMI and cost at the baseline, was 625 SEK per year (95% CI 304 -946). Also, the weight loss groups 5 -10% and 10 -15% showed a decrease in costs, but the difference in change as compared to the reference group < 5% was not statistically significant. Also, over the 6 y follow-up, the group with Effects of weight loss on pharmaceutical costs in obese subjects G Å gren et al weight loss 15% had a reduced average cost as compared to the reference group (Table 3 ). The relative decrease in medication cost was 38 and 27% in the weight loss group 15% at 2 and 6 y follow-up, respectively, as compared to an increase of 6 and 21% in the reference group (unadjusted changes). For subjects not on CVD medication at the baseline, the average cost per year in the reference group was 149 and 314 SEK at 2 and 6 y follow-up, respectively, as compared to 32 and 113 SEK in the weight loss 15% (adjusted difference -2 y, 117 SEK, 95% CI 21 -213; 6 y 201 SEK, 95% CI 63 -339, Table 3 ).
At 2 y follow-up, the average cost per year for diabetes medication increased from 1027 to 1533 SEK in the reference group, whereas in the other three weight loss groups the cost were reduced (Table 4) . The difference in the change as compared to the reference group was statistically significant for the 10 -15% and 15% groups. The relative decrease in cost in the 15% group was 78% at 2 y follow-up, as compared to an increase of 49% in the reference group (unadjusted changes). After 6 y, the only group that showed a reduced cost was the 15% group (adjusted difference in change as compared to the reference group -2201 SEK, 95% CI 739 -3664). Among those not on diabetes medication at the baseline, the average cost after 2 y was 0 SEK in the 10 -15% weight loss group and 2 SEK in the 15% group, reflecting the low proportion of subjects who started medication in those weight loss groups.
Over 6 y, the average annual costs for the two conditions, CVD and diabetes, taken together (those on and not on medication at baseline combined) increased by 463 SEK (from 480 to 943 SEK, a relative increase of 96%) in all subjects with weight loss < 5%, and decreased by 39 SEK (from 498 to 459 SEK, a relative decrease of 8%) in subjects with weight loss 15% ( Table 5 ). The difference in adjusted change between the two weight loss groups was 479 SEK (95% CI 252 -685).
Discussion
In this longitudinal intervention study of severely obese subjects, the proportion on medication for diabetes and CVD and the associated costs for medication were found to have improved among subjects who lost weight. The changes were somewhat more pronounced at 2 y follow-up as compared to 6 y follow-up. Improvements in medication Figure 1 Risk ratios (RR) with 95% confidence intervals (CI), and proportion of subjects on medication for cardiovascular disease (CVD) and diabetes at 2 and 6 y follow-up by weight change in the SOS study. Subjects were on respective medication at the baseline (n denotes total number of subjects in each group).
Effects of weight loss on pharmaceutical costs in obese subjects G Å gren et al Figure 2 Risk ratios (RR) with 95% confidence intervals (CI), and proportion of subjects on medication for cardiovascular disease (CVD) and diabetes at 2 and 6 y follow-up by weight change in the SOS study. Subjects not on medication at the baseline (n denotes total number of subjects in each group). a Adjusted to the mean values of sex, age and body mass index at baseline, and cost at baseline in the < 5% weight loss group. . *Statistically significant difference (P < 0.05) as compared to the < 5% weight loss group.
Effects of weight loss on pharmaceutical costs in obese subjects G Å gren et al costs in association with weight loss have been demonstrated in earlier studies with shorter follow-up times. 20, 21 The present study offers additional value in providing comparisons of changes in medication for different degrees of weight loss, as well as for the subjects who were initially free from medication. The results presented here are also in agreement with the reduced incidence of diabetes and CVD risk factors following surgical intervention. 17, 30 The estimates of the medication cost in this study were based on the longitudinal incidence and recovery data of the subjects. This allowed detailed analysis of change patterns not only among those who were affected at the baseline, but also among those who were free from medication when the study began. For those not on medication at the baseline, a weight reduction above 15% of initial body weight was required to show an improvement as compared to the reference group. In the group on medication at the baseline, a weight loss of 10 -15% resulted in an improvement as compared to the reference group, although the differences were reduced at 6 y follow-up as compared to 2 y follow-up. The changes in proportions were well reflected in the estimates of medication costs, in that the weight loss group 15% showed an improvement over the reference group in all cost comparisons. Weight loss of 10 -15% generally resulted in an improvement in medication costs over 2 y, but the differences were diminished at 6 y follow-up.
Although the results presented here generally agree with earlier studies by Greenway 20 and Collins, 21 the improvements among subjects on medication at the baseline were not as marked in our study. Greenway's study showed that in subjects treated with fenfluramine and either mazindol or phentermine, an average weight loss of 9% resulted in Adjusted to the mean values of sex, age, and body mass index at baseline, and cost at baseline in the < 5% weight loss group. . *Statistically significant difference (P < 0.05) as compared to the < 5% weight loss group.
Effects of weight loss on pharmaceutical costs in obese subjects G Å gren et al discontinuation of diabetes medication in all 26 subjects after an average of 7 weeks of follow-up. This can be compared to our study group where an average weight loss of 11.8% among the subjects on medication for diabetes resulted in 14 out of 53 subjects discontinuing the use of medication at 2 y follow-up. The average BMI and age at the baseline were similar in both studies. However, the distribution of gender differed markedly between the studies in that a majority of the subjects in our study were females. In gender-specific analyses, we observed a tendency toward better response among men as compared to women, although this did not reach statistical significance. Further, it is possible that the documented regain in weight during longer follow-up periods 30 contributes to the diluted longterm results observed in the current study.
To generalize the results observed in this study to an obese population, one must consider the following limitations. First, the subjects have been selected using a criterion which excludes patients with several morbid conditions. Therefore, the health state of the general obese population is worse as compared to the subjects in the SOS study. It is difficult to know how this affects the observed association with weight loss and improved medication of diabetes and CVD. Second, approximately 25% of the subjects dropped out of the study. Since the reasons for subjects leaving the study are not currently available for the research group (mortality data is handled by a separate safety monitoring committee, according to the study protocol), no attempt was made to analyze the reasons for drop out. However, there were no differences at the baseline in the use of CVD and diabetes medication between the completers and noncompleters. Third, the information on medication was collected from self-administered questionnaires. One cannot exclude the possibility that this could lead to misclassification bias regarding the use of medication. Finally, the number of subjects in some weight loss groups was small, affecting the power of the statistical tests. Still, prospective data on medication from a controlled 6 y obesity trial have so far not been published.
In order to attribute the observed changes in use of medication to weight loss per se, one has to assume that the general health care in the surgically and conventionally treated group was comparable, and that the use of medication was determined similarly in both groups. Still, the improved medication status and costs for medication after weight loss have been observed in studies involving different means to reduce weight, including very-low-caloric diet, 21 pharmacotherapeutic treatment 20 and, in the present study, surgical intervention. The results are generally consistent, indicating that the observed improvements are due to weight loss itself and not due to the methods used to achieve weight loss.
To estimate the total effects of weight loss on obesityrelated costs, one needs to consider other direct costs of obesity, including treatment and control for obesity itself and other obesity-related comorbid conditions. The Greenway study 20 reported an improvement in hyperlipidemic medication status. The number of subjects on medication for hypercholesterolemia in the present study was low and permitted no statistical analyses. The recent changes in the definitions of hypercholesterolemia and type 2 diabetes, and recommendations for treatment, are likely to increase the number of subjects on treatment and thereby also the medication costs. Further, studies describing the distribution and effects of weight loss on simultaneous comorbidities in the obese, and the corresponding costs for multiple comorbidities, are needed.
Detailed studies on other direct costs of obesity after weight loss are underway from the SOS study group, including number of hospital days, costs for hospitalization, and medications for other obesity-related comorbid conditions. Indirect costs, including absenteeism and disability pensions, have been associated with obesity 31 Data from the SOS study indicated that surgical treatment of obesity results in reduced sick leave and disability pension, 32 particularly in elderly subjects.
In addition to the previous short-term studies, showing improvements in medication costs for diabetes and CVD after weight loss in obese subjects, the present results elucidate the association between the degree of weight loss, changes in use of medication and associated costs, and length of follow-up. The effects of weight loss appear to be more marked among subjects who are initially on medication for these conditions, whereas greater, sustained weight reduction is needed to prevent new subjects from starting on medication.
